tiprankstipranks
Trending News
More News >
Altamira Therapeutics Ltd. (CYTOF)
:CYTOF
US Market
Advertisement

Altamira Therapeutics (CYTOF) Price & Analysis

Compare
597 Followers

CYTOF Stock Chart & Stats

$0.10
>-$0.01(-5.00%)
At close: 4:00 PM EST
$0.10
>-$0.01(-5.00%)

Altamira Therapeutics News

CYTOF FAQ

What was Altamira Therapeutics Ltd.’s price range in the past 12 months?
Altamira Therapeutics Ltd. lowest stock price was $0.05 and its highest was $0.62 in the past 12 months.
    What is Altamira Therapeutics Ltd.’s market cap?
    Altamira Therapeutics Ltd.’s market cap is $542.97K.
      When is Altamira Therapeutics Ltd.’s upcoming earnings report date?
      Altamira Therapeutics Ltd.’s upcoming earnings report date is Apr 15, 2026 which is in 172 days.
        How were Altamira Therapeutics Ltd.’s earnings last quarter?
        Altamira Therapeutics Ltd. released its earnings results on Aug 29, 2025. The company reported -$0.306 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.306.
          Is Altamira Therapeutics Ltd. overvalued?
          According to Wall Street analysts Altamira Therapeutics Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Altamira Therapeutics Ltd. pay dividends?
            Altamira Therapeutics Ltd. does not currently pay dividends.
            What is Altamira Therapeutics Ltd.’s EPS estimate?
            Altamira Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Altamira Therapeutics Ltd. have?
            Altamira Therapeutics Ltd. has 5,715,472 shares outstanding.
              What happened to Altamira Therapeutics Ltd.’s price movement after its last earnings report?
              Altamira Therapeutics Ltd. reported an EPS of -$0.306 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Altamira Therapeutics Ltd.?
                Currently, no hedge funds are holding shares in CYTOF

                Company Description

                Altamira Therapeutics Ltd.

                Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The firm focuses on the development of intranasal betahistine for the treatment of vertigo and for the prevention of antipsychotic-induced weight gain and somnolence. It also includes other programs under development such as Keyzilen, for the treatment of acute inner ear tinnitus; and Sonsuvi, for the treatment of acute inner ear hearing loss. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

                Altamira Therapeutics (CYTOF) Earnings & Revenues

                CYTOF Earnings Call

                Q2 2025
                0:00 / 0:00
                Earnings Call Sentiment|Neutral
                Altamira showed significant progress in its RNA delivery business with new partnerships and patent filings, while overcoming setbacks such as Nasdaq delisting and increased net loss. The strategy to involve private equity investors and spin-off RNA delivery activities indicates proactive steps for future growth.View all CYTOF earnings summaries
                Similar Stocks
                Company
                Price & Change
                Follow
                Biodexa Pharmaceuticals
                Q/C Technologies
                Salarius Pharmaceuticals
                Scinai Immunotherapeutics
                Oragenics

                Ownership Overview

                <0.01%100.00%
                Insiders
                <0.01% Other Institutional Investors
                100.00% Public Companies and
                Individual Investors

                Options Prices

                Currently, No data available
                ---
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis